ASND Ascendis Pharma A/S

115.81
-3.27  -3%
Previous Close 119.07
Open 122.5
Price To Book 14.07
Market Cap 4867576210
Shares 42,032,522
Volume 247,769
Short Ratio
Av. Daily Volume 419,781

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 4, 2019. Primary endpoint met. Data presented March 24, 2019 at ENDO 2019.
TransCon hGH
Growth hormone deficiency in children
Phase 2 trial initiation announced February 11, 2019 with top-line data due 4Q 2019.
TransCon
Hypoparathyroidism
Phase 2 trial to be intiated mid-2019.
TransCon CNP
Achondroplasia

Latest News

  1. Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
  2. Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth Hormone
  3. ValueAct Capital’s CBRE Recommendation Delivers 150% Gain
  4. What Makes Ascendis Pharma A/S (ASND) a New Buy Stock
  5. Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries — New Horizons, Emerging Trends, and Upcoming Developments
  6. Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602%
  7. Under the Radar Cannabis Stock-THC Therapeutics, Inc.
  8. Ascendis Pharma Prices 4.166M ADS Offering @$122/ADS
  9. Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
  10. Company News For Mar 5, 2019
  11. Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
  12. Why Ascendis Pharma Is Soaring Today
  13. Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
  14. Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia
  15. Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences — Renewed Outlook, Key Drivers of Growth
  16. Ascendis Pharma Files IND for Hypoparathyroidism Candidate
  17. Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism
  18. All You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to Buy
  19. Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT
  20. Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches